SFG
NBIX icon

Steward Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Steward Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3K Buy
+32
New +$3.37K ﹤0.01% 860
2023
Q2 		– Sell
-19
Closed -$1K – 798
2023
Q1 		$1K Buy
19
+5
+36% +$520 ﹤0.01% 635
2022
Q4 		$1K Buy
+14
New +$1.64K ﹤0.01% 441
2022
Q3 		– Sell
-11
Closed -$1K – 872
2022
Q2 		$1K Buy
+11
New +$1.01K ﹤0.01% 806

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Steward Financial Group's NBIX Position: Q3 2023 in Review

Steward Financial Group opened a new position in Neurocrine Biosciences (NBIX) in Q3 2023: 32 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #860 among its holdings. This is a return to the name: Steward Financial Group previously reported a position in NBIX as recently as Q1 2023.

Steward Financial Group first reported a position in NBIX in Q2 2022 and has held it in 4 quarters since. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • Steward Financial Group held 32 shares of Neurocrine Biosciences worth $3K as of Q3 2023.
  • Neurocrine Biosciences was a new Steward Financial Group position in Q3 2023.
  • Neurocrine Biosciences made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #860 holding.
  • Steward Financial Group first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 4 quarters since.
  • 511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.